Do analysts prefer HIND or FEED?

Vyome presently has a consensus price target of $15.00, indicating a potential upside of 552.17%. Given Vyome's stronger consensus rating and higher probable upside, research analysts clearly believe Vyome is more favorable than Nanovibronix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vyome 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Nanovibronix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is HIND or FEED more profitable?

Vyome has a net margin of 0.00% compared to Nanovibronix's net margin of -923.20%. Nanovibronix's return on equity of -54.25% beat Vyome's return on equity. Company Net Margins Return on Equity Return on Assets Vyome N/A -203.92% -134.16% Nanovibronix -923.20% -54.25% -43.10%

Do analysts recommend ICU or FEED?

SeaStar Medical currently has a consensus target price of $8.00, suggesting a potential upside of 62.60%. Given SeaStar Medical's stronger consensus rating and higher possible upside, research analysts clearly believe SeaStar Medical is more favorable than Nanovibronix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SeaStar Medical 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Nanovibronix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer OSRH or FEED?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OSR 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Nanovibronix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is OSRH or FEED more profitable?

OSR has a net margin of -363.26% compared to Nanovibronix's net margin of -923.20%. OSR's return on equity of -7.24% beat Nanovibronix's return on equity. Company Net Margins Return on Equity Return on Assets OSR -363.26% -7.24% -5.41% Nanovibronix -923.20% -54.25% -43.10%

Do analysts prefer FEED or FEMY?

Femasys has a consensus target price of $106.67, suggesting a potential upside of 2,457.95%. Given Femasys' stronger consensus rating and higher probable upside, analysts plainly believe Femasys is more favorable than Nanovibronix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nanovibronix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Femasys 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has preferable valuation and earnings, FEED or FEMY?

Nanovibronix has higher revenue and earnings than Femasys. Femasys is trading at a lower price-to-earnings ratio than Nanovibronix, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nanovibronix $2.55M 1.24 -$18.18M -$8.82 N/A Femasys $2.29M 5.50 -$18.63M -$5.40 N/A

Is FEED or FEMY more profitable?

Femasys has a net margin of -521.97% compared to Nanovibronix's net margin of -923.20%. Nanovibronix's return on equity of -54.25% beat Femasys' return on equity. Company Net Margins Return on Equity Return on Assets Nanovibronix -923.20% -54.25% -43.10% Femasys -521.97% -258.08% -73.72%

Do analysts recommend FEED or CODX?

Co-Diagnostics has a consensus price target of $67.50, indicating a potential upside of 2,157.53%. Given Co-Diagnostics' stronger consensus rating and higher probable upside, analysts plainly believe Co-Diagnostics is more favorable than Nanovibronix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nanovibronix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Co-Diagnostics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is FEED or CODX more profitable?

Nanovibronix has a net margin of -923.20% compared to Co-Diagnostics' net margin of -6,760.63%. Nanovibronix's return on equity of -54.25% beat Co-Diagnostics' return on equity. Company Net Margins Return on Equity Return on Assets Nanovibronix -923.20% -54.25% -43.10% Co-Diagnostics -6,760.63% -164.92% -141.15%

Nanovibronix (FEED) Competitors

$0.52 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$0.53 +0.01 (+2.12%)

As of 07/2/2026 07:33 PM Eastern

Compare

FEED vs. HIND, ICU, OSRH, FEMY, and CODX

Should you buy Nanovibronix stock or one of its competitors? MarketBeat compares Nanovibronix with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nanovibronix include Vyome (HIND), SeaStar Medical (ICU), OSR (OSRH), Femasys (FEMY), and Co-Diagnostics (CODX). These companies are all part of the "medical equipment" industry.

How does Nanovibronix compare to Vyome?

Vyome (NASDAQ:HIND) and Nanovibronix (NASDAQ:FEED) are both small-cap manufacturing companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, media sentiment, dividends, profitability and analyst recommendations.

22.1% of Vyome shares are held by institutional investors. Comparatively, 16.4% of Nanovibronix shares are held by institutional investors. 33.0% of Vyome shares are held by company insiders. Comparatively, 1.4% of Nanovibronix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Vyome presently has a consensus price target of $15.00, indicating a potential upside of 552.17%. Given Vyome's stronger consensus rating and higher probable upside, research analysts clearly believe Vyome is more favorable than Nanovibronix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vyome	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Nanovibronix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Vyome had 2 more articles in the media than Nanovibronix. MarketBeat recorded 2 mentions for Vyome and 0 mentions for Nanovibronix. Vyome's average media sentiment score of 1.10 beat Nanovibronix's score of 0.00 indicating that Vyome is being referred to more favorably in the media.

Company	Overall Sentiment
Vyome	Positive
Nanovibronix	Neutral

Vyome has higher earnings, but lower revenue than Nanovibronix. Vyome is trading at a lower price-to-earnings ratio than Nanovibronix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vyome	$320K	50.46	-$10.26M	-$12.27	N/A
Nanovibronix	$2.55M	1.24	-$18.18M	-$8.82	N/A

Vyome has a beta of 1.49, meaning that its stock price is 49% more volatile than the broader market. Comparatively, Nanovibronix has a beta of 1.56, meaning that its stock price is 56% more volatile than the broader market.

Vyome has a net margin of 0.00% compared to Nanovibronix's net margin of -923.20%. Nanovibronix's return on equity of -54.25% beat Vyome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vyome	N/A	-203.92%	-134.16%
Nanovibronix	-923.20%	-54.25%	-43.10%

Summary

Vyome beats Nanovibronix on 10 of the 16 factors compared between the two stocks.

How does Nanovibronix compare to SeaStar Medical?

SeaStar Medical (NASDAQ:ICU) and Nanovibronix (NASDAQ:FEED) are both small-cap medical equipment companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, risk and earnings.

SeaStar Medical has a net margin of -828.62% compared to Nanovibronix's net margin of -923.20%. Nanovibronix's return on equity of -54.25% beat SeaStar Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SeaStar Medical	-828.62%	-146.29%	-96.48%
Nanovibronix	-923.20%	-54.25%	-43.10%

1.7% of SeaStar Medical shares are held by institutional investors. Comparatively, 16.4% of Nanovibronix shares are held by institutional investors. 0.7% of SeaStar Medical shares are held by company insiders. Comparatively, 1.4% of Nanovibronix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

SeaStar Medical has a beta of -1.05, meaning that its stock price is 205% less volatile than the broader market. Comparatively, Nanovibronix has a beta of 1.56, meaning that its stock price is 56% more volatile than the broader market.

SeaStar Medical currently has a consensus target price of $8.00, suggesting a potential upside of 62.60%. Given SeaStar Medical's stronger consensus rating and higher possible upside, research analysts clearly believe SeaStar Medical is more favorable than Nanovibronix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SeaStar Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nanovibronix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

SeaStar Medical has higher earnings, but lower revenue than Nanovibronix. SeaStar Medical is trading at a lower price-to-earnings ratio than Nanovibronix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SeaStar Medical	$1.23M	16.00	-$12.15M	-$4.80	N/A
Nanovibronix	$2.55M	1.24	-$18.18M	-$8.82	N/A

In the previous week, SeaStar Medical's average media sentiment score of 0.00 equaled Nanovibronix'saverage media sentiment score.

Company	Overall Sentiment
SeaStar Medical	Neutral
Nanovibronix	Neutral

Summary

SeaStar Medical and Nanovibronix tied by winning 7 of the 14 factors compared between the two stocks.

How does Nanovibronix compare to OSR?

OSR (NASDAQ:OSRH) and Nanovibronix (NASDAQ:FEED) are both small-cap manufacturing companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

OSR has a beta of 0.72, meaning that its stock price is 28% less volatile than the broader market. Comparatively, Nanovibronix has a beta of 1.56, meaning that its stock price is 56% more volatile than the broader market.

Nanovibronix has lower revenue, but higher earnings than OSR. OSR is trading at a lower price-to-earnings ratio than Nanovibronix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OSR	$2.91M	3.87	-$27.06M	-$0.33	N/A
Nanovibronix	$2.55M	1.24	-$18.18M	-$8.82	N/A

55.3% of OSR shares are owned by institutional investors. Comparatively, 16.4% of Nanovibronix shares are owned by institutional investors. 36.8% of OSR shares are owned by insiders. Comparatively, 1.4% of Nanovibronix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

OSR has a net margin of -363.26% compared to Nanovibronix's net margin of -923.20%. OSR's return on equity of -7.24% beat Nanovibronix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OSR	-363.26%	-7.24%	-5.41%
Nanovibronix	-923.20%	-54.25%	-43.10%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OSR	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Nanovibronix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, OSR had 2 more articles in the media than Nanovibronix. MarketBeat recorded 2 mentions for OSR and 0 mentions for Nanovibronix. OSR's average media sentiment score of 0.25 beat Nanovibronix's score of 0.00 indicating that OSR is being referred to more favorably in the media.

Company	Overall Sentiment
OSR	Neutral
Nanovibronix	Neutral

Summary

OSR beats Nanovibronix on 10 of the 13 factors compared between the two stocks.

How does Nanovibronix compare to Femasys?

Nanovibronix (NASDAQ:FEED) and Femasys (NASDAQ:FEMY) are both small-cap medical equipment companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

16.4% of Nanovibronix shares are owned by institutional investors. Comparatively, 65.3% of Femasys shares are owned by institutional investors. 1.4% of Nanovibronix shares are owned by company insiders. Comparatively, 7.8% of Femasys shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Nanovibronix has higher revenue and earnings than Femasys. Femasys is trading at a lower price-to-earnings ratio than Nanovibronix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanovibronix	$2.55M	1.24	-$18.18M	-$8.82	N/A
Femasys	$2.29M	5.50	-$18.63M	-$5.40	N/A

In the previous week, Nanovibronix's average media sentiment score of 0.00 equaled Femasys'average media sentiment score.

Company	Overall Sentiment
Nanovibronix	Neutral
Femasys	Neutral

Nanovibronix has a beta of 1.56, suggesting that its stock price is 56% more volatile than the broader market. Comparatively, Femasys has a beta of -2.13, suggesting that its stock price is 313% less volatile than the broader market.

Femasys has a consensus target price of $106.67, suggesting a potential upside of 2,457.95%. Given Femasys' stronger consensus rating and higher probable upside, analysts plainly believe Femasys is more favorable than Nanovibronix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanovibronix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Femasys has a net margin of -521.97% compared to Nanovibronix's net margin of -923.20%. Nanovibronix's return on equity of -54.25% beat Femasys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nanovibronix	-923.20%	-54.25%	-43.10%
Femasys	-521.97%	-258.08%	-73.72%

Summary

Femasys beats Nanovibronix on 8 of the 14 factors compared between the two stocks.

How does Nanovibronix compare to Co-Diagnostics?

Nanovibronix (NASDAQ:FEED) and Co-Diagnostics (NASDAQ:CODX) are both small-cap medical equipment companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.

Nanovibronix has higher revenue and earnings than Co-Diagnostics. Co-Diagnostics is trading at a lower price-to-earnings ratio than Nanovibronix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanovibronix	$2.55M	1.24	-$18.18M	-$8.82	N/A
Co-Diagnostics	$718.17K	15.34	-$46.90M	-$15.77	N/A

Nanovibronix has a beta of 1.56, meaning that its share price is 56% more volatile than the broader market. Comparatively, Co-Diagnostics has a beta of 2.84, meaning that its share price is 184% more volatile than the broader market.

In the previous week, Co-Diagnostics had 4 more articles in the media than Nanovibronix. MarketBeat recorded 4 mentions for Co-Diagnostics and 0 mentions for Nanovibronix. Nanovibronix's average media sentiment score of 0.00 equaled Co-Diagnostics'average media sentiment score.

Company	Overall Sentiment
Nanovibronix	Neutral
Co-Diagnostics	Neutral

Co-Diagnostics has a consensus price target of $67.50, indicating a potential upside of 2,157.53%. Given Co-Diagnostics' stronger consensus rating and higher probable upside, analysts plainly believe Co-Diagnostics is more favorable than Nanovibronix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanovibronix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Co-Diagnostics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

16.4% of Nanovibronix shares are held by institutional investors. Comparatively, 15.0% of Co-Diagnostics shares are held by institutional investors. 1.4% of Nanovibronix shares are held by company insiders. Comparatively, 5.4% of Co-Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Nanovibronix has a net margin of -923.20% compared to Co-Diagnostics' net margin of -6,760.63%. Nanovibronix's return on equity of -54.25% beat Co-Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nanovibronix	-923.20%	-54.25%	-43.10%
Co-Diagnostics	-6,760.63%	-164.92%	-141.15%

Summary

Nanovibronix beats Co-Diagnostics on 8 of the 15 factors compared between the two stocks.

Get Nanovibronix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FEED and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FEED vs. The Competition

Export

Metric	Nanovibronix	Surgical, Medical, And Dental Instruments And Supplies Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$3.17M	$3.23B	$5.20B	$12.48B
Dividend Yield	N/A	N/A	16.11%	6.52%
P/E Ratio	-0.06	20.07	23.91	24.70
Price / Sales	1.24	389.38	216.83	99.49
Price / Cash	N/A	9.27	35.06	57.09
Price / Book	0.02	5.79	13.25	6.46
Net Income	-$18.18M	$7.39M	$113.80M	$337.01M
7 Day Performance	-9.74%	0.70%	0.93%	1.69%
1 Month Performance	-40.16%	-0.17%	1.08%	3.81%
1 Year Performance	N/A	-38.62%	10.03%	23.90%

Nanovibronix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FEED Nanovibronix	0.2844 of 5 stars	$0.52 flat	N/A	N/A	$3.17M	$2.55M	N/A	20	Gap Up
HIND Vyome	3.8815 of 5 stars	$2.10 -0.9%	$15.00 +614.3%	N/A	$14.88M	$320K	N/A	50	News Coverage
ICU SeaStar Medical	2.5374 of 5 stars	$3.09 -11.0%	$8.00 +158.9%	-8.6%	$13.87M	$1.23M	N/A	2	Gap Down
OSRH OSR	0.8546 of 5 stars	$0.34 -6.6%	N/A	-76.3%	$12.67M	$2.91M	N/A	N/A	News Coverage Gap Down
FEMY Femasys	1.9724 of 5 stars	$3.67 -8.5%	$106.67 +2,806.4%	-77.7%	$12.11M	$2.29M	N/A	30	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FEED) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nanovibronix (FEED) Competitors

FEED vs. HIND, ICU, OSRH, FEMY, and CODX

How does Nanovibronix compare to Vyome?

Summary

How does Nanovibronix compare to SeaStar Medical?

Summary

How does Nanovibronix compare to OSR?

Summary

How does Nanovibronix compare to Femasys?

Summary

How does Nanovibronix compare to Co-Diagnostics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FEED vs. The Competition

Nanovibronix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nanovibronix (FEED) Competitors

FEED vs. HIND, ICU, OSRH, FEMY, and CODX

How does Nanovibronix compare to Vyome?

Do institutionals and insiders believe in HIND or FEED?

Do analysts prefer HIND or FEED?

Does the media refer more to HIND or FEED?

Which has higher earnings and valuation, HIND or FEED?

Which has more volatility and risk, HIND or FEED?

Is HIND or FEED more profitable?

Summary

How does Nanovibronix compare to SeaStar Medical?

Is ICU or FEED more profitable?

Do institutionals and insiders have more ownership in ICU or FEED?

Which has more risk & volatility, ICU or FEED?

Do analysts recommend ICU or FEED?

Which has stronger earnings and valuation, ICU or FEED?

Does the media favor ICU or FEED?

Summary

How does Nanovibronix compare to OSR?

Which has more volatility and risk, OSRH or FEED?

Which has preferable valuation and earnings, OSRH or FEED?

Do institutionals and insiders believe in OSRH or FEED?

Is OSRH or FEED more profitable?

Do analysts prefer OSRH or FEED?

Does the media refer more to OSRH or FEED?

Summary

How does Nanovibronix compare to Femasys?

Do institutionals & insiders hold more shares of FEED or FEMY?

Which has preferable valuation and earnings, FEED or FEMY?

Does the media favor FEED or FEMY?

Which has more volatility & risk, FEED or FEMY?

Do analysts prefer FEED or FEMY?

Is FEED or FEMY more profitable?

Summary

How does Nanovibronix compare to Co-Diagnostics?

Which has stronger earnings and valuation, FEED or CODX?

Which has more risk and volatility, FEED or CODX?

Does the media prefer FEED or CODX?

Do analysts recommend FEED or CODX?

Do institutionals & insiders believe in FEED or CODX?

Is FEED or CODX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FEED vs. The Competition

Nanovibronix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools